IGN-523

N/A

Report date: 2024/03/20 11:14:18

Base Information

Drug NameIGN-523

Drug Alias Nameanti-CD98 monoclonal antibodyIGN-523

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsAmino acid transporter heavy chain SLC3A2 inhibitors

TargetsAmino acid transporter heavy chain SLC3A2

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesIgenica

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesIgenica Biotherapeutics Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A